IP Library › Granted Patent US 10,377,759
Granted Patent B2
US 10,377,759 · App. 15/738,485 · Granted Aug 13, 2019

Brk inhibitory compound

Inventors: Shingo Yamamoto (Osaka, JP); Hiroshi Tokura (Osaka, JP); Masakuni Kurono (Osaka, JP); Yoshinori Nomura (Osaka, JP); Shingo Hotta (Osaka, JP)
Assignee: ONO PHARMACEUTICAL CO., LTD.
C07D487/04A61K31/519A61K31/53A61K39/395A61K45/00A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,377,759
App. No.
15/738,485
Granted
Aug 13, 2019
Kind
B2
Abstract

The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.

Claims (4)

1. N 6 -(1,3-dimethyl-1H-pyrazol-4-yl)-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

a salt thereof, a solvate thereof, or an N-oxide thereof.

2. A compound represented by structural formula as below,

3. A salt of a compound represented by structural formula as below,

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2017
From: YAMAMOTO, SHINGO; TOKURA, HIROSHI; KURONO, MASAKUNI; NOMURA, YOSHINORI; HOTTA, SHINGO
To: ONO PHARMACEUTICAL CO., LTD.
Reel/Frame 044452/0979 →
Priority Claims (1)
JP 2015-124315 · Jun 22, 2015 · national
Continuity (1)
Related Publication 20180186800A1 · Jul 5, 2018
Cited By (2)
US 12,187,725 US 12,643,910